当行业迈入1 . 1万亿规模的高位平台，真正决定品牌命运的，不再是一次营销战役的胜负，而 是能否在高度同质化的市场中构建清晰的价值坐标。喷雾，这一曾被贴上"基础补水" "随手一 喷"的入门级品类，恰好映射出这种变化。 它看似门槛不高，实则竞争密集；价格带相对集中，替代选择丰富。在这样的赛道里，品牌若 没有稳定的技术标签与持续的内容表达，很容易被淹没在更新迭代的浪潮中。也正因如此，当 一个喷雾品类能够在激烈竞争中成长为营收支柱时，往往也是品牌系统能力的集中体现。 与此同时，当下消费者的决策机制正在发生微妙变化。年轻群体对"成分" "功效" "科研背景"的 关注度显著提升，同时也更加在意品牌所传递的价值立场与精神气质。代言人不再只是流量入 口，而成为品牌人格的外化象征；产品升级也不只是参数堆叠，而是一种对消费认知升级的回 应。 在这样的行业坐标下， 颐莲在马年续约张凌赫为品牌喷雾全球代言人，同步上新胶原蛋白喷 雾新品 ，我们有必要追问：一个国货品牌如何在存量竞争时代构建长期优势？又如何让科技 实力与文化表达形成合力，而非彼此割裂的两条叙事线？ 答案，就隐藏在接下来的故事之中。 在竞争愈发激烈的护肤市场，品牌与明星 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook following the divestiture of its real estate business and steady growth in the cosmetics segment [5][42]. Core Insights - The company has transitioned its main business focus to cosmetics and pharmaceuticals after divesting its real estate operations in 2023. The cosmetics segment has shown resilience, contributing over 52.8% of total revenue [10][41]. - The company is leveraging a "product + R&D + channel" strategy to build competitive advantages, focusing on marketing synergies, innovation in product development, and a comprehensive online and offline sales network [8][30][34]. - Revenue projections for 2025-2027 are estimated at RMB 38.1 billion, RMB 39.3 billion, and RMB 43.0 billion, with corresponding growth rates of -4.3%, +3.1%, and +9.5% respectively. Net profit is expected to reach RMB 2.4 billion, RMB 2.7 billion, and RMB 3.1 billion during the same period [9][41]. Summary by Sections Market Performance - The closing price of the stock is RMB 7.36, with a total market capitalization of RMB 7,481.95 million and a circulating market value of RMB 7,481.95 million [3]. Financial Data - The company reported a gross margin of 46.49% in 2023, a significant increase of 21.84 percentage points from the previous year, primarily due to the strategic shift away from low-margin real estate operations [21]. Revenue and Profit Forecast - The company anticipates a decline in revenue for 2023, followed by a gradual recovery, with net profit growth projected at +0.2%, +8.8%, and +15.3% for the years 2025 to 2027 [9][41]. Business Segments - The cosmetics segment is expected to see revenue growth of -5%, +6%, and +14% from 2025 to 2027, while the pharmaceutical segment is projected to grow at -5%, -3%, and +5% during the same period [10][41]. - The raw materials and additives segment is forecasted to grow steadily, with revenue increases of +3%, +4%, and +5% from 2025 to 2027 [10]. Competitive Positioning - The company is positioned favorably against comparable domestic brands, with a projected price-to-earnings (P/E) ratio of 28 times for 2026, aligning with industry averages [42]. Marketing and R&D Strategy - The company has invested significantly in R&D, with a budget of RMB 1.16 billion for the first three quarters of 2025, representing a research expense ratio of 4.47% [30]. - New product launches and marketing initiatives are focused on enhancing brand visibility and consumer engagement across various channels, including e-commerce and physical retail [28][34]. Sales Channels - The cosmetics segment's revenue is heavily driven by online sales, contributing 84.2% of total revenue, while offline sales account for 15.8% [34]. - The company is expanding its presence in both online and offline markets, establishing flagship stores on major e-commerce platforms and increasing the number of physical retail locations [34].

Core Viewpoint - The company, Lushang Freda Pharmaceutical Co., Ltd., reported a decline in revenue and profit for the first half of 2025, primarily due to challenges in the cosmetics and pharmaceutical sectors, including product iteration and pricing pressures from expanded procurement policies [1][2][3]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 1.79 billion yuan for the first half of 2025, a decrease of 7.05% compared to the same period last year [2]. - The total profit for the period was approximately 153 million yuan, down 17.31% year-on-year [2]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was approximately 107.96 million yuan, reflecting a decrease of 15.16% [2]. - The total assets of the company at the end of the reporting period were approximately 6.04 billion yuan, showing a slight increase of 0.61% from the previous year [2]. Industry and Main Business Situation - The company operates in the cosmetics, pharmaceuticals, and raw materials sectors, with a focus on product innovation and market expansion [3][5]. - The domestic cosmetics market has shown signs of slowing growth, with retail sales growth of cosmetics lagging behind overall retail sales growth [3]. - The pharmaceutical sector is facing challenges due to expanded procurement policies and price reductions for winning products, impacting revenue generation [3][5]. Business Performance - The cosmetics segment reported a revenue of approximately 5.54 billion yuan, a year-on-year increase of 23.78%, while the brand "Aier Doctor" saw a significant revenue decline of 29.97% [10][11]. - The company has launched over 80 new products in the cosmetics sector during the reporting period, including key products from various brands [12][13]. - The pharmaceutical segment has been actively developing new products and enhancing brand visibility through participation in industry conferences and events [11][14]. Sales and Marketing Strategies - The company has established a comprehensive online and offline sales network, with online sales accounting for 84.20% of total revenue in the cosmetics segment [11]. - The marketing strategy includes leveraging social media and e-commerce platforms for brand promotion and customer engagement [10][11]. - The company is focusing on enhancing its product offerings and optimizing pricing strategies to improve market competitiveness [10][11]. Research and Development - The company has made significant advancements in research and development, particularly in the field of hyaluronic acid, which is widely used across various industries [3][8]. - The R&D efforts are supported by collaborations with academic institutions and the establishment of technology innovation systems [12][14]. - The company has received multiple certifications for its production facilities, emphasizing its commitment to quality and sustainability [15].